Putative neuroprotective agents in neuropsychiatric disorders
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness. This includes progressive structural brain changes, cognitive and functional decline, poorer treatment response and an increasing vulnerability to relapse with chronicity. The underlying molecular mechanisms of neuroprogression are thought to include neurotrophins and regulation of neurogenesis and apoptosis, neurotransmitters, inflammatory, oxidative and nitrosative stress, mitochondrial dysfunction, cortisol and the hypothalamic-pituitary-adrenal axis, and epigenetic influences. Knowledge of the involvement of each of these pathways implies that specific agents that act on some or multiple of these pathways may thus block this cascade and have neuroprotective properties. This paper reviews the potential of the most promising of these agents, including lithium and other known psychotropics, aspirin, minocycline, statins, N-acetylcysteine, leptin and melatonin. These agents are putative neuroprotective agents for schizophrenia and mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.013 · Cited by 1,742
The mechanism of action of aspirin
Vane, J. R., & Botting, R. M. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00379-7 · Cited by 1,225
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationMaes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Self-citationBora, E., Fornito, A., Pantelis, C., & Yücel, M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.049 · Cited by 763
Gawryluk, J. W., Wang, J.-F., Andreazza, A. C., Shao, L., & Young, L. T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000805 · Cited by 594
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Self-citationKubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.026 · Cited by 443
Self-citationN -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Self-citationMitochondrial dysfunction and pathology in bipolar disorder and schizophrenia
Clay, H. B., Daws, S., & Konradi, C. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.08.007 · Cited by 399
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Hulshoff Pol, H. E., & Kahn, R. S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm168 · Cited by 364
Frommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
Self-citationNeuroinflammation in schizophrenia especially focused on the role of microglia
Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314
Omega-3 for Bipolar Disorder: Meta-Analyses of Use in Mania and Bipolar Depression
Sarris, J., Mischoulon, D., & Schweitzer, I. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06710 · Cited by 284
Bora, E., Harrison, B. J., Davey, C. G., Yücel, M., & Pantelis, C. (2012) · Psychological Medicine · doi:10.1017/s0033291711001668 · Cited by 276
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
Antidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide
Hashioka, S., Klegeris, A., Monji, A., Kato, T., Sawada, M., McGeer, P. L., & Kanba, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.022 · Cited by 198
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Self-citationReduced anterior cingulate and orbitofrontal volumes in child abuse-related complex PTSD
Thomaes, K., Dorrepaal, E., Draijer, N., de Ruiter, M. B., van Balkom, A. J., Smit, J. H., & Veltman, D. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04754blu · Cited by 173
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Cui, J., Shao, L., Young, L. T., & Wang, J.-F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.010 · Cited by 160
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
Miyaoka, T., Yasukawa, R., Yasuda, H., Hayashida, M., Inagaki, T., & Horiguchi, J. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181593d45 · Cited by 146
Minocycline: Therapeutic Potential in Psychiatry
Dean, O. M., Data-Franco, J., Giorlando, F., & Berk, M. (2012) · CNS Drugs · doi:10.2165/11632000-000000000-00000 · Cited by 131
Self-citationZhang, W., Hu, X., Yang, W., Gao, Y., & Chen, J. (2010) · Stroke · doi:10.1161/strokeaha.110.586081 · Cited by 127
Gałecki, P., Szemraj, J., Bieńkiewicz, M., Zboralski, K., & Gałecka, E. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1014 · Cited by 124
Anderson, G., & Maes, M. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9307-9 · Cited by 105
Self-citationKynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects
Muller, N., Myint, A.-M., & J. Schwarz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049552 · Cited by 94
Cited by
ROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Treasure, J., Stein, D., & Maguire, S. (2015) · Early Intervention in Psychiatry · doi:10.1111/eip.12170 · Cited by 353
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Sommer, I. E., van Westrhenen, R., Begemann, M. J. H., de Witte, L. D., Leucht, S., & Kahn, R. S. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt139 · Cited by 342
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Yang, A., & Tsai, S.-J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081689 · Cited by 282
Lopresti, A. L., & Drummond, P. D. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.05.005 · Cited by 231
Metadata
- Authors
- Dodd, S., Maes, M., Anderson, G., Dean, O. M., Moylan, S., & Berk, M.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 42
- Pages
- 135-145
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2077339937
- Cited by
- 104
- References
- 28
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.